Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

CellaVision AB (0MR5) Share Price & Analysis

0 Followers

0MR5 Stock Chart & Stats

kr 202.50-kr 1.00(-0.49%)
At close: 4:30 PM GMT
kr 150kr 175kr 200Aug 17Sep 3Sep 14Sep 28Oct 13Oct 26Nov 9
Day’s Range
SEK 201.50 - SEK 202.50
52-Week Range
SEK 118.80 - SEK 204.00
Previous Close
SEK 203.50
Volume
N/A
Average Volume (3M)
1,551
Market Cap
SEK 4.84B
Enterprise Value
SEK 3.96B
Total Cash (Recent Filing)
SEK 218.54M
Total Debt (Recent Filing)
SEK 49.81M
Price to Earnings (P/E)
35.0
Beta
1.18
Next Earnings
Feb 04, 2027 (Est.)
EPS Estimate
2.03
Next Dividend Ex-Date
N/A
Dividend Yield
1.33%

Bulls Say, Bears Say

Bulls Say

Low Leverage And Balance-sheet Resilience

Debt-to-equity of about 0.05, growing equity and healthy ROE give CellaVision substantial financial resilience. This supports continued investment in product development and commercial expansion while reducing balance-sheet risk that could restrict execution during weaker laboratory spending cycles.

Recurring Revenue Expansion

Recurring reagent revenue can make the installed base more valuable over time because sales rise with laboratory testing volumes. This creates a steadier revenue foundation than instrument sales alone and may deepen customer relationships as CellaVision becomes embedded in diagnostic workflows.

Product And Innovation Pipeline

Progress in FPM and next-generation analyzers provides a durable avenue for product renewal and broader laboratory adoption. Higher image quality and throughput could strengthen CellaVision’s differentiation, while potential pathology and cytology applications expand its long-term addressable opportunities.

Bears Say

Revenue Growth Has Decelerated

The pronounced slowdown from historical growth rates indicates that expansion is currently less broad or less rapid than earlier in the cycle. Even with healthy profitability, slower revenue growth can limit operating leverage, reduce investment capacity, and increase dependence on successful new products.

Regional Healthcare-spending Pressure

Pressure on healthcare investment in China and across EMEA can lengthen purchasing decisions and delay laboratory automation projects. The regional weakness matters beyond one quarter because constrained public healthcare budgets may make adoption and sales recovery less predictable in important markets.

Margin Pressure From Mix And Amortization

Lower gross margin and higher development amortization reduce the earnings contribution from each sale, even though overall profitability remains strong. Management expects amortization to stay elevated until the next product launches, creating an ongoing margin headwind during the current product transition.

CellaVision AB News

0MR5 FAQ

What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest share price was kr 118.80 and its highest was kr 204.00 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is kr 4.84B.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s next earnings report is estimated for Feb 04, 2027 (not yet confirmed), which is in 84 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Oct 29, 2026. The company reported kr 1.725 earnings per share for the quarter, beating the consensus estimate of kr 1.425 by kr 0.3.
Is CellaVision AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does CellaVision AB pay dividends?
CellaVision AB does not currently pay dividends.
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 2.03.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of kr 1.725 in its last earnings report, beating expectations of kr 1.425. Following the earnings report the stock price went up 4.577%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in GB:0MR5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology